Sana Biotechnology (SANA) Total Non-Current Liabilities (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Total Non-Current Liabilities data on file, last reported at $171.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 24.58% year-over-year to $171.2 million; the trailing twelve-month figure through Mar 2026 stood at $171.2 million (down 24.58% YoY), and the FY2025 full-year result was $245.4 million, up 1.99% from the prior year.
• Total Non-Current Liabilities retreated to $171.2 million in Q1 2026, from $245.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $259.5 million in Q3 2024 to a low of $168.2 million in Q4 2023.
• A 5-year average of $224.5 million and a median of $232.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities decreased 28.44% in 2022 and surged 43.07% in 2024, its largest moves.
• Tracing SANA's Total Non-Current Liabilities over 5 years: stood at $228.4 million in 2022, then slipped by 26.35% to $168.2 million in 2023, then jumped by 43.07% to $240.6 million in 2024, then advanced by 1.99% to $245.4 million in 2025, then tumbled by 30.26% to $171.2 million in 2026.
• Business Quant data shows SANA's Total Non-Current Liabilities at $171.2 million in Q1 2026, $245.4 million in Q4 2025, and $232.2 million in Q3 2025.